Year 2 £3,002,813 £6,237,257 £3,234,444 Year 3 £3,058,613 £6,571,656 £3,513,043
Year 4 £3,110,853 £6,740,635 £3,629,782 Year 5 It is expected that a total of 8,007 patients will be eligible to receive EVE+EXE over a five-year period. In a 'world without EVE+EXE', the total five year cost was estimated as £12,877,522.
Assuming an annual uptake rate of 10%, in a 'world with EVE+EXE' the total cost over the same period was expected to be £21,652,706. Therefore, the incremental cost associated with the introduction of EVE+EXE in England and Wales is £8,775,184 over five years.
Results
The model uses a cumulative cohort approach, allowing incident patients to enter the model each year over a five-year period. The incident population was based on several factors: (i) the female population aged >15 years; (ii) the proportion of those women with advanced invasive breast cancer; (iii) the proportion who are post-menopausal; (iv) the proportion who are hormone receptor positive; (v) the proportion for who are HER2-; (vi) the proportion with asymptomatic visceral disease, and (vii) the proportion for whom hormonal therapy is appropriate. Finally, the cohort was filtered to show those who had previously relapsed or progressed on NSAI. The total number of women with advanced breast cancer was calculated using NICE Clinical Guideline 81 Costing Template. Per patient treatment and adverse event costs were generated based on treatment-specific progression-free survival curves, and multiplied by the number of patients expected to receive each treatment according to market share data and likely uptake rates. Drug costs were taken from BNF62. Adverse event costs were taken from NHS Reference Costs 2009-10. An incremental analysis was performed, where two scenarios were compared: (i) a world without EVE+EXE, and (ii) a world with EVE+EXE.
